However, it selectively inhibits the psoriasis-associated pathogenic factor IL-17 and chemokine receptor CCR6 in differentiated Th17 cells through the c-Jun N-terminal kinase (JNK) pathway transcription in differentiated Th17 cells (49). Here, MAPK8 is linked to psoriasis.